Will I be locked into a contract
Riccardo De Giorgi, Clinical Lecturer at the University of Oxfords Department of Psychiatry and NIHR BRC: Oxford Health researcher said: Whether GLP-1RAs can be useful for the treatment of major neurocognitive disorders, such as dementia, is a highly debated area
## Availability Status: March 2026 - **FDA status:** Phase 3 clinical trials ongoing - **Expected approval timeline:** Potentially 2026-2027 - **Brand availability:** None yet - **Current access:** Compounding pharmacies (503A/503B) with valid prescription For a detailed breakdown of [retatrutide's FDA approval status and projected timeline](/guides/retatrutide-fda-approval-2026-timeline-status), see our dedicated tracker the date brand pricing becomes available depends directly on when retatrutide clears FDA review
People taking GLP-1s experience fewer chemo side effects In a separate study, researchers compared the health records of more than 5,600 people with breast cancer who were getting chemotherapy and using GLP-1s with people with breast cancer who were getting chemo and not taking GLP-1s
On the other hand, Wegovy is started on a lower dose of 0.25mg subcutaneously once weekly and this dosage increases every four weeks by an additional .25mg until reaching its maximum dose of 2.4mg/week for chronic weight management in adult patients who are overweight or obese
Dihexa (chemical name: N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic neuropeptide developed by researchers at Washington State University (WSU)
